NASDAQ: COAG

Hemab Therapeutics Holdings, Inc.

CIK 0002114044 · Biological Products

Small by assets Assets $175M as of Jul 5, 2026

Each report below shows a 3-bullet preview. Free accounts read 3 full reports a month — narrative summary, section diffs, and EDGAR-cited quotes.

Sign up free

Want to see a complete report first? Today's free report (ADMT 10-K) is open in full — no account needed.

10-Q Filed May 21, 2026 · Period ending Mar 31, 2026 Red flag

Hemab discloses material control weaknesses in debut 10-Q; $317M IPO extends runway to 2029

5 material changes detected. Sign up free to read the summary.

View report
8-K Filed May 21, 2026 · Period ending May 21, 2026

Hemab Therapeutics reports Q1 2026 financial results

2 material changes detected. Sign up free to read the summary.

View report

Partner

Trade COAG commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

8-K Filed May 11, 2026 · Period ending May 8, 2026

Hemab Therapeutics board member Laura Tadvalkar resigns effective immediately

1 material change detected. Sign up free to read the summary.

View report
8-K Filed May 4, 2026 · Period ending May 4, 2026

Hemab Therapeutics completes $346.7M IPO at $18/share, adopts anti-takeover defenses

5 material changes detected. Sign up free to read the summary.

View report
View all filings for COAG on SEC EDGAR